NRX Pharmaceuticals, Inc. Chief Financial Officer Michael S. Abrams filed a Form 4 on November 4, 2026, disclosing the acquisition of 75,000 restricted stock units granted on July 28, 2026.

Key Highlights

  • Reporting person: Michael S. Abrams, Chief Financial Officer of NRX Pharmaceuticals, Inc. (NASDAQ:NRXP)
  • Security awarded: 75,000 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock
  • Transaction date: July 28, 2026, with transaction code A (acquired)
  • Price paid: $0 per RSU, according to the filing
  • Vesting schedule: Three equal annual installments on July 28, 2027, July 28, 2028, and July 28, 2029, subject to continued service
  • Post-transaction holdings: 75,000 derivative securities (RSUs) beneficially owned directly following the reported transaction
  • Plan: Granted under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan, as amended

Michael Abrams RSU Award Details: NRX Pharmaceuticals July 2026 Grant

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Michael S. Abrams, serving as Chief Financial Officer of NRX Pharmaceuticals, Inc. (NASDAQ:NRXP), was awarded 75,000 restricted stock units on July 28, 2026. The filing reports the transaction under code "A," indicating an acquisition, at a price of $0. Abrams's address is listed care of NRX Pharmaceuticals, Inc., 1201 Orange Street, Suite 600, Wilmington, Delaware 19801.

The filing states that each RSU "represents a contingent right to receive one share of the Issuer's common stock at the time of vesting for no consideration." The RSUs were granted under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan, as amended. According to the filing, the units vest "in three equal annual installments on July 28, 2027, July 28, 2028 and July 28, 2029, subject to the reporting person's continued service through each vesting date."

Following the reported transaction, Abrams beneficially owns 75,000 RSUs directly, with no non-derivative securities reported in Table I of the filing. The Form 4 was signed by Michael Abrams and dated November 4, 2026, and was filed as an individual (one reporting person) rather than a joint or group filing.

What Was Disclosed

The filing disclosed that NRX Pharmaceuticals CFO Michael S. Abrams acquired 75,000 RSUs on July 28, 2026, at no cost, under the company's 2021 Omnibus Incentive Plan. The units vest in equal thirds over three years beginning July 28, 2027.